TherapeuticsMD Announces Positive Top-Line Results from its Phase 3 Rejoice Trial in Postmenopausal Women with Vulvar and Vaginal Atrophy (VVA) Treated with 25 mcg, 10 mcg or 4 mcg of TX-004HR

Conference Call Scheduled for Today at 4:45 p.m. ET to Discuss Results

BOCA RATON, Fla.–(BUSINESS WIRE)–TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women’s healthcare
company, today announced positive top-line results from its pivotal
Phase 3 Rejoice Trial of TX-004HR, an investigational, applicator-free
vaginal estradiol softgel, for the treatment of moderate to severe
dyspareunia (vaginal pain during sexual intercourse), a symptom of
vulvar and vaginal atrophy (VVA) due to menopause. VVA is a chronic
condition affecting nearly half of postmenopausal women in the United
States that can significantly impair their quality of life.

TX-004HR was evaluated at 25 mcg, 10 mcg, and 4 mcg doses. The
pre-specified four co-primary endpoints were the change from baseline to
week 12 in the percentage of vaginal superficial cells, percentage of
vaginal parabasal cells, vaginal pH, and in participants’ self-reported
severity of dyspareunia as the most bothersome symptom of VVA.

Statistical Significance of Results for Co-Primary Endpoints
(Based on Mean Change from Baseline to Week 12 Compared to
    25 mcg   10 mcg   4 mcg
Superficial Cells   P < 0.0001   P < 0.0001   P < 0.0001
Parabasal Cells   P < 0.0001   P < 0.0001   P < 0.0001
Vaginal pH   P < 0.0001   P < 0.0001   P < 0.0001
Severity of Dyspareunia   P = 0.0001   P = 0.0001   P = 0.0255

The 25 mcg dose of TX-004HR demonstrated highly statistically
significant results at the p ≤ 0.0001 level compared to placebo across
all four co-primary endpoints. The 10 mcg dose of TX-004HR demonstrated
highly statistically significant results at the p ≤ 0.0001 level
compared to placebo across all four co-primary endpoints. The 4 mcg dose
of TX-004HR also demonstrated highly statistically significant results
at the p ≤ 0.0001 level compared to placebo for the endpoints of vaginal
superficial cells, vaginal parabasal cells, and vaginal pH; the change
from baseline compared to placebo in the severity of dyspareunia was at
the p = 0.0255 level.

Statistical improvement over placebo was also observed for all three
doses at the first assessment at week two and sustained through week 12.
The pharmacokinetic data for all three doses demonstrated low systemic
absorption, supporting the previous Phase 1 trial data. TX-004HR was
well tolerated, and there were no clinically significant differences
compared to placebo-treated participants with respect to adverse events.
There were no drug-related serious adverse events reported. Additional
presentations of this data are included at the end of this press release.

“We are extremely encouraged that all three doses of TX-004HR studied in
the Rejoice Trial demonstrated positive results,” said TherapeuticsMD
CEO Robert G. Finizio. “With efficacy observed as early as two weeks and
the convenience of the applicator-free vaginal softgel, we believe that,
if approved, TX-004HR has the potential to offer a highly
differentiated, new treatment option that meets the needs of the
millions of postmenopausal women with VVA who are suffering from pain
during sexual intercourse. We look forward to sharing the Rejoice Trial
results and to submitting a New Drug Application for TX-004HR to the
Food and Drug Administration as soon as the first half of 2016.”

TX-004HR features SYMBODATM technology, which enables partial
and complete solubilization of estradiol into medium-chain fatty acid
oils often derived from coconut oil. This allows for the production of
cohesive, stable formulations and provides content uniformity and
accuracy of dosing strengths for TX-004HR.

“Nearly half of all postmenopausal women have VVA, yet few are treated
with prescription therapy,” said TherapeuticsMD Chief Medical Officer
Sebastian Mirkin, M.D. “The highly statistically significant efficacy
results and safety profile from the Rejoice Trial are very promising. We
are excited about the potential for TX-004HR to be a new treatment
option with low systemic absorption for women with VVA suffering from
moderate to severe dyspareunia.”

Safety and efficacy analyses of the Rejoice Trial data are ongoing.
TherapeuticsMD plans to submit Rejoice Trial results for presentation at
future scientific meetings and for publication in peer reviewed journals.

Rejoice Trial Design

The Rejoice Trial was a randomized, double-blinded, placebo-controlled,
multicenter Phase 3 clinical trial designed to evaluate the safety and
efficacy of three doses of TX-004HR — 25 mcg, 10 mcg and 4 mcg —
compared to placebo for the treatment of moderate to severe dyspareunia
in postmenopausal women with VVA. The co-primary efficacy endpoints are
change from baseline to week 12 in the percentage of vaginal superficial
cells, percentage of vaginal parabasal cells, vaginal pH, and severity
of moderate to severe dyspareunia as the most bothersome symptom of VVA.
The trial enrolled 764 postmenopausal women (40 to 75 years old)
experiencing moderate to severe dyspareunia at approximately 89 sites
across the United States and Canada. Trial participants were randomized
to receive either TX-004HR at 25 mcg (n=190), 10 mcg (n=191), or 4 mcg
(n=191) doses or placebo (n=192) for a total of 12 weeks, all
administered once daily for two weeks and then twice weekly
(approximately three to four days apart) for ten weeks.

Conference Call and Webcast

TherapeuticsMD will host a conference call today, during which
management will discuss the top-line results of the pivotal Phase 3
Rejoice Trial. Details for the call are:

Date: December 7, 2015

Time: 4:45 p.m. ET

Telephone Access (US): (866) 665-9531

Telephone Access (International): (724) 987-6977

Access Code for All Callers: 98389089

Additionally, a live webcast can be accessed on the company’s website,,
under the “Investors & Media” section.

About TX-004HR

TX-004HR is an investigational bio-identical 17β-estradiol vaginal drug
product candidate being studied for the treatment of moderate to severe
dyspareunia, a symptom of VVA, also known as genitourinary syndrome of
menopause (GSM), in postmenopausal women. TX-004HR utilizes a unique
applicator-free vaginal estradiol softgel capsule technology.

About Vulvar and Vaginal Atrophy (VVA)

An estimated 32 million women in the United States are currently
suffering from symptoms of VVA1, and only 2.3 million (7%)
are currently being treated with prescription therapy.2,3 The
burden of VVA in the United States may increase due to aging of the
population.4 Furthermore, due to increasing longevity,4 women
may now suffer from VVA or other conditions related to decreased
reproductive hormone levels for over one-third of their lives.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative healthcare company focused on
developing and commercializing products exclusively for women. With its
SYMBODA technology, TherapeuticsMD is developing advanced
hormone therapy pharmaceutical products to enable delivery of
bio-identical hormones through a variety of dosage forms and
administration routes. The company’s clinical development pipeline
includes two phase 3 products. The company also manufactures and
distributes branded and generic prescription prenatal vitamins as well
as over-the-counter vitamins under the vitaMedMD® and
BocaGreenMD® brands. More information is available at the
following websites:,

Forward Looking Statements

This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include, but
are not limited to, statements relating to TherapeuticsMD’s objectives,
plans and strategies as well as statements, other than historical facts,
that address activities, events or developments that the company
intends, expects, projects, believes or anticipates will or may occur in
the future. These statements are often characterized by terminology such
as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,”
“plans,” “will,” “expects,” “estimates,” “projects,” “positioned,”
“strategy” and similar expressions and are based on assumptions and
assessments made in light of management’s experience and perception of
historical trends, current conditions, expected future developments and
other factors believed to be appropriate. Forward-looking statements in
this press release are made as of the date of this press release, and
the company undertakes no duty to update or revise any such statements,
whether as a result of new information, future events or otherwise.
Forward-looking statements are not guarantees of future performance and
are subject to risks and uncertainties, many of which are outside of the
company’s control. Important factors that could cause actual results,
developments and business decisions to differ materially from
forward-looking statements are described in the sections titled “Risk
Factors” in the company’s filings with the Securities and Exchange
Commission, including its most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and
include the following: the company’s ability to maintain or increase
sales of its products; the company’s ability to develop and
commercialize its hormone therapy drug candidates and obtain additional
financing necessary therefor; the length, cost and uncertain results of
the company’s clinical trials; the potential of adverse side effects or
other safety risks that could preclude the approval of the company’s
hormone therapy drug candidates; the company’s reliance on third parties
to conduct its clinical trials, research and development and
manufacturing; the availability of reimbursement from government
authorities and health insurance companies for the company’s products;
the impact of product liability lawsuits; the influence of extensive and
costly government regulation; the volatility of the trading price of the
company’s common stock and the concentration of power in its stock
ownership. PDF copies of the company’s historical press releases and
financial tables can be viewed and downloaded at its website:


1 Kingsberg SA, Wysocki S, Magnus L, et al. Vulvar and
vaginal atrophy in postmenopausal women: Findings from the Revive (REal
Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs)
survey. J Sex Med. 2013;10:1790-1799.

2 Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo
Clin Proc.

3 North American Menopause Society. The role of local vaginal
estrogen for treatment of vaginal atrophy in postmenopausal women: 2007
position statement of The North American Menopause Society. Menopause.
2007; l4(3 Pt 1):355-69.

4 US Census Bureau. Age and Sex Composition: 2010. 2011 May.
Report No.: C2010BR-03.


Cartwright, 561-961-1900
Chief Financial Officer,
Fox, 212-257-6724
Director, Media & Engagement, WCG